Bank of New York Mellon Corp Has $5.14 Million Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Bank of New York Mellon Corp boosted its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 8.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 124,328 shares of the company's stock after purchasing an additional 9,629 shares during the quarter. Bank of New York Mellon Corp owned 0.26% of Mirum Pharmaceuticals worth $5,141,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Rhumbline Advisers boosted its stake in shares of Mirum Pharmaceuticals by 2.4% in the fourth quarter. Rhumbline Advisers now owns 53,113 shares of the company's stock valued at $2,196,000 after buying an additional 1,236 shares during the period. Legato Capital Management LLC increased its position in shares of Mirum Pharmaceuticals by 7.9% in the fourth quarter. Legato Capital Management LLC now owns 13,395 shares of the company's stock worth $554,000 after purchasing an additional 977 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth $413,000. Empowered Funds LLC acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $1,376,000. Finally, Golden State Equity Partners lifted its position in Mirum Pharmaceuticals by 1,390.8% during the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company's stock worth $801,000 after purchasing an additional 18,080 shares during the period.

Mirum Pharmaceuticals Trading Down 1.9 %

NASDAQ:MIRM traded down $0.90 on Friday, reaching $46.97. 428,630 shares of the stock traded hands, compared to its average volume of 512,997. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $54.23. The company's 50 day moving average is $47.77 and its 200-day moving average is $43.65. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -23.25 and a beta of 1.04.

Remove Ads

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. HC Wainwright lifted their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $58.20.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 1,998 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $85,554.36. Following the transaction, the chief operating officer now directly owns 27,015 shares of the company's stock, valued at approximately $1,156,782.30. The trade was a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Peetz sold 7,489 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the sale, the chief executive officer now directly owns 119,359 shares of the company's stock, valued at approximately $5,110,952.38. This trade represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 133,679 shares of company stock worth $6,007,081 in the last 90 days. Corporate insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.